Enhancing the Anticancer Activity of Sorafenib through Its Combination with a Nitric Oxide Photodelivering β-Cyclodextrin Polymer.
chemotherapy
cyclodextrin polymers
light
nitric oxide
sorafenib
Journal
Molecules (Basel, Switzerland)
ISSN: 1420-3049
Titre abrégé: Molecules
Pays: Switzerland
ID NLM: 100964009
Informations de publication
Date de publication:
16 Mar 2022
16 Mar 2022
Historique:
received:
16
02
2022
revised:
07
03
2022
accepted:
12
03
2022
entrez:
26
3
2022
pubmed:
27
3
2022
medline:
31
3
2022
Statut:
epublish
Résumé
In this contribution, we report a strategy to enhance the therapeutic action of the chemotherapeutic Sorafenib (SRB) through its combination with a multifunctional β-cyclodextrin-based polymer able to deliver nitric oxide (NO) and emit green fluorescence upon visible light excitation (PolyCDNO). The basically water-insoluble SRB is effectively encapsulated in the polymeric host (1 mg mL
Identifiants
pubmed: 35335280
pii: molecules27061918
doi: 10.3390/molecules27061918
pmc: PMC8953797
pii:
doi:
Substances chimiques
Cyclodextrins
0
Polymers
0
beta-Cyclodextrins
0
cyclodextrin polymer
0
Nitric Oxide
31C4KY9ESH
Cellulose
9004-34-6
Sorafenib
9ZOQ3TZI87
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
Biomacromolecules. 2014 May 12;15(5):1768-76
pubmed: 24673610
Invest New Drugs. 2018 Jun;36(3):370-379
pubmed: 29116478
Expert Opin Investig Drugs. 2012 Apr;21(4):557-68
pubmed: 22394203
ACS Med Chem Lett. 2017 Jan 30;8(3):361-365
pubmed: 28337331
Chem Commun (Camb). 2013 May 18;49(40):4459-61
pubmed: 23571637
Nitric Oxide. 2013 Nov 1;34:56-64
pubmed: 23416089
Biomater Sci. 2019 May 28;7(6):2272-2276
pubmed: 31033967
J Control Release. 2017 Nov 28;266:47-56
pubmed: 28917533
Chem Commun (Camb). 2020 Jun 11;56(47):6332-6335
pubmed: 32435776
Chemistry. 2021 Sep 6;27(50):12714-12725
pubmed: 34143909
Int J Nanomedicine. 2020 Mar 05;15:1469-1480
pubmed: 32184599
Nat Rev Mol Cell Biol. 2002 Mar;3(3):214-20
pubmed: 11994742
J Mater Chem B. 2014 Mar 7;2(9):1190-1195
pubmed: 32261355
Chem Soc Rev. 2014 Jun 21;43(12):4167-78
pubmed: 24306531
Curr Oncol. 2009 May;16 Suppl 1:S27-32
pubmed: 19478894
Free Radic Biol Med. 1998 Sep;25(4-5):434-56
pubmed: 9741580
J Med Chem. 2017 Sep 28;60(18):7617-7635
pubmed: 28505442
Oncologist. 2009 Jan;14(1):95-100
pubmed: 19144678
Int J Nanomedicine. 2021 Dec 23;16:8309-8321
pubmed: 34992367
Sci Rep. 2019 Feb 5;9(1):1430
pubmed: 30723285
World J Clin Oncol. 2016 Aug 10;7(4):331-6
pubmed: 27579253
Chem Soc Rev. 2012 May 21;41(10):3742-52
pubmed: 22362384
J Control Release. 2016 Jan 10;221:62-70
pubmed: 26551344
Drug Des Devel Ther. 2016 Mar 11;10:1119-31
pubmed: 27042004
Oncotarget. 2017 Jun 6;8(23):38022-38043
pubmed: 28410237
Mol Pharm. 2015 Feb 2;12(2):484-95
pubmed: 25495614
Cancer Res. 2005 Jan 15;65(2):516-25
pubmed: 15695394
Chem Soc Rev. 2010 Aug;39(8):2903-13
pubmed: 20556272
Acc Chem Res. 2011 Apr 19;44(4):289-98
pubmed: 21361269
Basic Clin Pharmacol Toxicol. 2015 Mar;116(3):216-21
pubmed: 25495944
Nat Rev Cancer. 2006 Jul;6(7):521-34
pubmed: 16794635
Biochem Pharmacol. 2020 Jun;176:113855
pubmed: 32061562
Free Radic Biol Med. 2015 Feb;79:324-36
pubmed: 25464273
Int J Pharm. 2014 May 15;466(1-2):172-80
pubmed: 24607205
Biomater Sci. 2020 Mar 7;8(5):1329-1344
pubmed: 31912808
Chem Rev. 2002 Apr;102(4):1091-134
pubmed: 11942788
Chemistry. 2019 May 23;25(29):7091-7095
pubmed: 30913331
Cancers (Basel). 2014 Sep 05;6(3):1769-92
pubmed: 25198391
Mol Pharm. 2020 Jun 1;17(6):2135-2144
pubmed: 32286080
Asian J Pharm Sci. 2021 May;16(3):318-336
pubmed: 34276821
Signal Transduct Target Ther. 2020 Jun 10;5(1):87
pubmed: 32532960
Free Radic Biol Med. 1995 Dec;19(6):785-94
pubmed: 8582651
Mol Cancer Ther. 2012 Oct;11(10):2284-93
pubmed: 22902857
Carcinogenesis. 1998 May;19(5):711-21
pubmed: 9635855